Macrophages, lipid metabolism and gene expression in atherogenesis: A therapeutic target of the future?

Clinical Lipidology

Volumn 7, Issue 1, 2012, Pages 37-48

  Michael, Daryn R ^a   Ashlin, Tim G ^a   Buckley, Melanie L ^a   Ramji, Dipak P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

anti inflammatory therapy; atherosclerosis; cholesterol; foam cell; macrophage; nuclear receptor agonist; statin

Indexed keywords

APOLIPOPROTEIN A1; CANAKINUMAB; DARAPLABID; DOXYCYCLINE; ETANERCEPT; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 33; LIVER X RECEPTOR AGONIST; MICRORNA; MLN 1202; MONOCLONAL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHOLIPASE A2 INHIBITOR; PIOGLITAZONE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; SECUKINUMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROMATOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CHOLESTEROL HOMEOSTASIS; CHOLESTEROL METABOLISM; CHOLESTEROL STORAGE; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; FATTY LIVER; FOAM CELL; GENE EXPRESSION; HEART INFARCTION; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; RHEUMATOID ARTHRITIS; STROKE;

EID: 84856932962     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.73     Document Type: Review

References (90)

1. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 145(3), 341-355 (2011).
2. Mclaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog. Lipid Res. 50(4), 331-347 (2011).
3. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347), 317-325 (2011).
4. Tabas I. Macrophage death and defective infammation resolution in atherosclerosis. Nat. Rev. Immunol. 10(1), 36-46 (2010).
5. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17(11), 1410-1422 (2011).
6. Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 37(3), 208-222 (2006). (Pubitemid 43106595)
7. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116(16), 1832-1844 (2007). (Pubitemid 350287108)
8. Saha P, Modarai B, Humphries J et al. The monocyte/macrophage as a therapeutic target in atherosclerosis. Curr. Opin. Pharmacol 9(2), 109-118 (2009).
9. Goldstein J, Ho Y, Basu S, Brown M. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl Acad. Sci. USA 76(1), 333-337 (1979). (Pubitemid 9110191)
10. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis 53(3), 265-271 (1984). (Pubitemid 15194149)
11. Klurfeld DM. Identifcation of foam cells in human atherosclerotic lesions as macrophages using monoclonal antibodies. Arch. Pathol. Lab. Med. 109(5), 445-449 (1985). (Pubitemid 15052661)
12. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice defcient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl Acad. Sci. USA 92(18), 8264-8268 (1995).
13. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 12(3), 204-212 (2011).
14. Shimada K. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ. J. 73(6), 994-1001 (2009).
15. Gleissner CA, Shaked I, Little KM, Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J. Immunol. 184(9), 4810-4818 (2010).
16. Hirose K, Iwabuchi K, Shimada K et al. Different responses to oxidized low-density lipoproteins in human polarized macrophages. Lipids Health Dis. 10, 1 (2011).
17. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 7(2), 77-86 (2010).
18. Ikonen E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol. Rev. 86(4), 1237-1261 (2006). (Pubitemid 44521652)
19. van der Velde AE. Reverse cholesterol transport: from classical view to new insights. World J. Gastroenterol. 16(47), 5908-5915 (2010).
20. Plüddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods 43(3), 207-217 (2007). (Pubitemid 47499075)
21. Moore K, Freeman M. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler. Thromb. Vasc. Biol. 26(8), 1702-1711 (2006). (Pubitemid 44305322)
22. Nozaki S, Kashiwagi H, Yamashita S et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-defcient subjects. J. Clin. Invest. 96(4), 1859-1865 (1995).
23. Sugano R, Yamamura T, Harada-Shiba M, Miyake Y, Yamamoto A. Uptake of oxidized low-density lipoprotein in a THP-1 cell line lacking scavenger receptor A. Atherosclerosis 158(2), 351-357 (2001). (Pubitemid 32913644)
24. Mitra S, Goyal T, Mehta JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc. Drugs Ther. 25(5), 419-429 (2011).
25. Zhang L, Liu HJ, Li TJ et al. Lentiviral vector-mediated siRNA knockdown of SR-PSOX inhibits foam cell formation in vitro. Acta Pharmacol. Sin. 29(7), 847-852 (2008).
26. Smith EB, Ashall C. Low-density lipoprotein concentration in interstitial fuid from human atherosclerotic lesions. Relation to theories of endothelial damage and lipoprotein binding. Biochim. Biophys. Acta 754(3), 249-257 (1983). (Pubitemid 14216902)
27. Kerr M, Teasdale R. Defning macropinocytosis. Traffc 10(4), 364-371 (2009).
28. Mclaren JE, Michael DR, Guschina IA, Harwood JL, Ramji DP. Eicosapentaenoic acid and docosahexaenoic acid regulate modifed LDL uptake and macropinocytosis in human macrophages. Lipids 46(11), 1053-1061 (2011).
29. Anzinger JJ, Chang J, Xu Q et al. Native low-density lipoprotein uptake by macrophage colony-stimulating factor-differentiated human macrophages is mediated by macropinocytosis and micropinocytosis. Arterioscler. Thromb. Vasc. Biol. 30(10), 2022-2031 (2010).
30. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol effux and immune responses. Arterioscler. Thromb. Vasc. Biol. 30(2), 139-143 (2010).
31. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol effux: implications for the treatment of atherosclerosis. Cell. Metab. 7(5), 365-375 (2008). (Pubitemid 351598023)
32. Bodzioch M, Orso E, Klucken J et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22(4), 347-351 (1999). (Pubitemid 29369524)
33. Mukhamedova N, D'Souza W, Low H, Kesani R, Chimini G, Sviridov D. Global functional knockdown of ATP binding cassette transporter A1 stimulates development of atherosclerosis in apoE K/O mice. Biochem. Biophys. Res. Commun. 412(3), 446-449 (2011).
34. Sankaranarayanan S, Oram JF, Asztalos BF et al. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol effux. J. Lipid Res. 50(2), 275-284 (2009).
35. Greenow K, Pearce NJ, Ramji DP. The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. (Berl.) 83(5), 329-342 (2005). (Pubitemid 41201798)
36. Lucic D, Huang ZH, Gu de S, Altenburg MK, Maeda N, Mazzone T. Regulation of macrophage ApoE secretion and sterol effux by the LDL receptor. J. Lipid Res. 48(2), 366-372 (2007). (Pubitemid 46220603)
37. Lin CY, Lucas M, Mazzone T. Endogenous ApoE expression modulates HDL3 binding to macrophages. J. Lipid Res. 39(2), 293-301 (1998). (Pubitemid 28100667)
38. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-defcient mice by bone marrow transplantation. Science 267(5200), 1034-1037 (1995).
39. Fazio S, Babaev VR, Murray AB et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc. Natl Acad. Sci. USA 94(9), 4647-4652 (1997). (Pubitemid 27194297)
40. Ji Y, Jian B, Wang N et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol effux. J. Biol. Chem. 272(34), 20982-20985 (1997). (Pubitemid 27373951)
41. de la Llera-Moya M, Rothblat GH, Connelly MA et al. Scavenger receptor BI (SR-BI) mediates free cholesterol fux independently of HDL tethering to the cell surface. J. Lipid Res. 40(3), 575-580 (1999). (Pubitemid 29116161)
42. Zhang W, Yancey PG, Su YR et al. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-defcient mice. Circulation 108(18), 2258-2263 (2003). (Pubitemid 37363044)
43. Covey SD, Krieger M, Wang W, Penman M, Trigatti BL. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler. Thromb. Vasc. Biol. 23(9), 1589-1594 (2003). (Pubitemid 37108202)
44. Hoekstra M, Van Berkel TJ, Van Eck M. Scavenger receptor BI: a multi-purpose player in cholesterol and steroid metabolism. World J. Gastroenterol. 16(47), 5916-5924 (2010).
45. Chinetti-Gbaguidi G, Staels B. Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages. Biochim. Biophys. Acta 1791(6), 486-493 (2009).
46. Sekiya M, Osuga J, Igarashi M, Okazaki H, Ishibashi S. The role of neutral cholesterol ester hydrolysis in macrophage foam cells. J. Atheroscler. Thromb. 18(5), 359-364 (2011).
47. McLaren J, Calder C, McSharry B et al. The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro. J. Immunol. 184(10), 5827-5834 (2010).
48. McLaren JE, Michael DR, Salter RC et al. IL-33 reduces macrophage foam cell formation. J. Immunol. 185(2), 1222-1229 (2010).
49. Klingenberg R, Hansson GK. Treating infammation in atherosclerotic cardiovascular disease: emerging therapies. Eur. Heart J. 30(23), 2838-2844 (2009).
50. Koga M, Kai H, Yasukawa H et al. Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ. Res. 101(4), 348-356 (2007). (Pubitemid 47267703)
51. Abbate A, Salloum FN, Vecile E et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117(20), 2670-2683 (2008).
52. Olofsson PS, Sheikine Y, Jatta K et al. A functional interleukin-1 receptor antagonist polymorphism infuences atherosclerosis development. The interleukin-1beta: interleukin-1 receptor antagonist balance in atherosclerosis. Circ. J. 73(8), 1531-1536 (2009).
53. Atzeni F, Turiel M, Caporali R et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun. Rev. 9(12), 835-839 (2010).
54. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr. Opin. Rheumatol. 23(3), 245-251 (2011).
55. Chen S, Shimada K, Zhang W, Huang G, Crother TR, Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J. Immunol. 185(9), 5619-5627 (2010).
56. Dretzke J, Edlin R, Round J et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infiximab, for Crohn's disease. Health Technol. Assess. 15(6), 1-244 (2011).
57. Kerekes G, Soltész P, Dér H et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann. NY Acad. Sci. 1173, 814-821 (2009).
58. Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler. Thromb. Vasc. Biol. 28(6), 1050-1059 (2008).
59. Szanto A, Roszer T. Nuclear receptors in macrophages: a link between metabolism and infammation. FEBS Lett. 582(1), 106-116 (2008). (Pubitemid 350297244)
60. Bouhlel MA, Staels B, Chinetti-Gbaguidi G. Peroxisome proliferator-activated receptors-from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. J. Intern. Med. 263(1), 28-42 (2008). (Pubitemid 350243555)
61. Calkin AC, Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30(8), 1513-1518 (2010).
62. Sivagnanam G. Rosiglitazone and macular edema. CMAJ 175(3), 276 (2006).
63. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007). (Pubitemid 46919772)
64. Im SS, Osborne TF. Liver X receptors in atherosclerosis and infammation. Circ. Res. 108(8), 996-1001 (2011).
65. Li N, Salter RC, Ramji DP. Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J. Cell. Biochem. 112(2), 675-683 (2011).
66. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov. 10(11), 835-852 (2011).
67. Sadeghi MM, Glover DK, Lanza GM, Fayad ZA, Johnson LL. Imaging atherosclerosis and vulnerable plaque. J. Nucl. Med. 51(Suppl. 1), S51-S65 (2010).
68. Charo IF, Taub R. Anti-infammatory therapeutics for the treatment of atherosclerosis. Nat. Rev. Drug Discov. 10(5), 365-376 (2011).
69. Bench TJ, Jeremias A, Brown DL. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacol. Res. 64(6), 561-566 (2011).
70. Corson MA. Darapladib: an emerging therapy for atherosclerosis. Ther. Adv. Cardiovasc. Dis. 4(4), 241-248 (2010).
71. White H, Held C, Stewart R et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) comparing darapladib versus placebo in patients with coronary heart disease. Am. Heart J. 160(4), 655-661 (2010).
72. Croons V, Martinet W, de Meyer GR. Selective removal of macrophages in atherosclerotic plaques as a pharmacological approach for plaque stabilization: benefts versus potential complications. Curr. Vasc. Pharmacol. 8(4), 495-508 (2010).
73. Evans M, Roberts A, Davies S, Rees A. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs 64(11), 1181-1196 (2004). (Pubitemid 38858287)
74. Jain MK, Ridker PM. Anti-infammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4(12), 977-987 (2005).
75. Hofnagel O, Luechtenborg B, Weissen-Plenz G, Robenek H. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim. Biophys. Acta 1771(9), 1117-1124 (2007). (Pubitemid 47407789)
76. Mizuno Y, Jacob RF, Mason R P. Infammation and the development of atherosclerosis. J. Atheroscler. Thromb. 18(5), 351-358 (2011).
77. Nachtigal P, Pospisilova N, Jamborova G et al. Atorvastatin has hypolipidemic and anti-infammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci. 82(13-14), 708-717 (2008).
78. Quist-Paulsen P. Statins and infammation: an update. Curr. Opin. Cardiol. 25(4), 399-405 (2010).
79. Libby P, Okamoto Y, Rocha VZ, Folco E. Infammation in atherosclerosis: transition from theory to practice. Circ. J. 74(2), 213-220 (2010).
80. Taylor F, Ward K, Moore TH et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 (2011).
81. Getz GS, Wool GD, Reardon CA. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other infammatory disorders. Curr. Pharm. Des. 16(28), 3173-3184 (2010).
82. Haas MJ, Mooradian AD. Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection. Drugs 70(7), 805-821 (2010).
83. Tardif JC, Gregoire J, L'allier PL et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297(15), 1675-1682 (2007). (Pubitemid 46631626)
84. Meyer P, Nigam A, Marcil M, Tardif JC. The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease. Curr. Atheroscler. Rep. 11(5), 329-333 (2009).
85. Bloedon LT, Dunbar R, Duffy D et al. Safety, pharmacokinetics, and pharmacodynamics of oral ApoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49(6), 1344-1352 (2008).
86. Martin K, O'Sullivan JF, Caplice NM. New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture. Curr. Opin. Cardiol. 26(6), 569-575 (2011).
87. Haver VG, Slart RH, Zeebregts CJ, Peppelenbosch MP, Tio RA. Rupture of vulnerable atherosclerotic plaques: microRNAs conducting the orchestra? Trends Cardiovasc. Med. 20(2), 65-71 (2010).
88. Huang RS, Hu GQ, Lin B, Lin ZY, Sun CC. MicroRNA-155 silencing enhances infammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J. Investig. Med. 58(8), 961-967 (2010).
89. Rayner KJ, Esau CC, Hussain FN et al Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478 (7369), 404-407 (2011).
90. Vickers KC, Remaley AT. MicroRNAs in atherosclerosis and lipoprotein metabolism. Curr. Opin. Endocrinol. Diabetes Obes. 17(2), 150-155 (2010).